- Home
- ANAB vs MNRO Comparison
ANAB vs MNRO Comparison
Compare ANAB & MNRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- MNRO
- Stock Information
- Founded
- ANAB 2005
- MNRO 1957
- Country
- ANAB United States
- MNRO United States
- Employees
- ANAB N/A
- MNRO N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- MNRO Automotive Aftermarket
- Sector
- ANAB Health Care
- MNRO Consumer Discretionary
- Exchange
- ANAB Nasdaq
- MNRO Nasdaq
- Market Cap
- ANAB 621.1M
- MNRO 658.9M
- IPO Year
- ANAB 2017
- MNRO 1991
- Fundamental
- Price
- ANAB $23.41
- MNRO $16.63
- Analyst Decision
- ANAB Buy
- MNRO Buy
- Analyst Count
- ANAB 10
- MNRO 4
- Target Price
- ANAB $44.25
- MNRO $21.00
- AVG Volume (30 Days)
- ANAB 566.9K
- MNRO 865.3K
- Earning Date
- ANAB 08-04-2025
- MNRO 07-30-2025
- Dividend Yield
- ANAB N/A
- MNRO 6.74%
- EPS Growth
- ANAB N/A
- MNRO N/A
- EPS
- ANAB N/A
- MNRO N/A
- Revenue
- ANAB $111,872,000.00
- MNRO $1,195,334,000.00
- Revenue This Year
- ANAB N/A
- MNRO $0.31
- Revenue Next Year
- ANAB $24.39
- MNRO $2.42
- P/E Ratio
- ANAB N/A
- MNRO N/A
- Revenue Growth
- ANAB 387.20
- MNRO N/A
- 52 Week Low
- ANAB $12.21
- MNRO $12.20
- 52 Week High
- ANAB $41.31
- MNRO $31.49
- Technical
- Relative Strength Index (RSI)
- ANAB 57.46
- MNRO 62.35
- Support Level
- ANAB $21.87
- MNRO $13.51
- Resistance Level
- ANAB $24.69
- MNRO $15.00
- Average True Range (ATR)
- ANAB 1.19
- MNRO 0.74
- MACD
- ANAB -0.09
- MNRO 0.18
- Stochastic Oscillator
- ANAB 61.20
- MNRO 95.41
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About MNRO Monro Inc.
Monro Inc is a provider automobile service stations in the United States. Through its network of company-owned service stations, Monro Muffler Brake offers maintenance, repair, tire, and fleet management services for automobiles focused largely on undercar services such as brake, steering, exhaust, drivetrain, and suspension systems. Next to service stores, the company also offers tire stores specialised in tire replacement and service.